Category Archives: ALS Treatment

A Phase 1b proof-of-concept clinical trial of the experimental oral therapy VRG50635 in people with amyotrophic lateral sclerosis (ALS) is expected to launch in the coming months, according to the therapys developer, Verge Genomics. Continue reading →

NEW YORK, Nov. 29, 2023 /PRNewswire/ -- ProJenX, a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other debilitating brain diseases, today announced authorization of its clinical trial application (CTA) by Health Canada for study PRO-101, a global, hybrid Phase 1 clinical trial evaluating prosetina first-in-class MAP4K inhibitorin healthy volunteers and participants with ALS Continue reading →

- PHOENIX Phase 3 trial topline results on track for mid-2024 and will inform regulatory next steps in the EU - Final decision from the European Commission expected by the end of 2023 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. Continue reading →

Amyotrophic lateral sclerosis (ALS) patients not eligible to participate in clinical trials of pridopidine a small molecule developed by Prilenia Therapeutics to slow disease progression in ALS will soon be able to receive the experimental therapy via an expanded access program (EAP). EAPs, also known as compassionate-use programs, are aimed at people with serious or life-threatening conditions that have few or no adequate treatments. Continue reading →

People with amyotrophic lateral sclerosis (ALS) due to mutations in the FUS gene may benefit from interferon-gamma treatment to delay disease onset and/or progression, an early preclinical study suggests. Researchers found that an immune signaling protein called interferon (INF)-gamma protected patient-derived motor neurons from oxidative stress Continue reading →

Heather Cleveland Heather Cleveland shares about her diagnosis, next weekends fundraiser and hope for a cure Heather Cleveland has been a staple of the Granbury scene for decades both as a businesswoman, and as an involved participant in the local art scene. Cleveland was diagnosed with Amyotrophic Lateral Sclerosis (ALS) in May 2021 Continue reading →

Magen David Adom (MDA), is a national EMS organization on the front lines of the war. On the morning of October 7, 30 minutes before the night shift was about to end, MDA emergency phone operators began receiving calls of injuries along the Gaza strip and the settlements of the Western Negev, under the cover of rocket barrages. Continue reading →

CLENE INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)   Marketscreener.com Continue reading →

Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. Continue reading →

For Immediate Release: May 05, 2017 The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrigs disease. After learning about the use of edaravone to treat ALS in Japan, we rapidly engaged with the drug developer about filing a marketing application in the United States, said Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDAs Center for Drug Evaluation and Research Continue reading →